<?xml version="1.0" encoding="UTF-8"?>

<?xml-stylesheet type="text/xsl" href="/static/oaitohtml.xsl"?>

<!--
<?xml-stylesheet type="text/xsl" href="/oaitohtml.xsl"?>
-->

<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <responseDate>2026-10-14T12:03:23Z</responseDate>
    <request verb="GetRecord" metadataPrefix="oai_dc" identifier="10.57760/sciencedb.26908" >https://www.scidb.cn/oai</request>
<GetRecord>
    <record>
    <header >
    <identifier>10.57760/sciencedb.26908</identifier>
    <datestamp>2025-06-24T10:27:03Z</datestamp>
</header>
    <metadata>
        
<oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:date>2025-06-24</dc:date>
  <dc:title>Frontiers_1591615_raw data.</dc:title>
  <dc:identifier>doi:10.57760/sciencedb.26908</dc:identifier>
  <dc:language>en</dc:language>
  <dc:description>This dataset originates from a comprehensive study investigating the functional role of the RGC32 gene in diffuse large B-cell lymphoma (DLBCL), integrating histological, molecular biological, and in vitro/in vivo experimental data.Figure 1: Expression Profiling and Prognostic Significance of RGC32 in DLBCLData Content:1A: RGC32 immunohistochemical (IHC) staining images of 80 DLBCL and 32 reactive hyperplasia lymph node (RHL) tissues (scale bar = 5 &amp;mu;m).1B: Kaplan-Meier survival analysis data tables for progression-free survival (PFS) and overall survival (OS) (unit: months) from 74 patient records, with groups stratified by RGC32 expression threshold (low-expression group &amp;le;7, high-expression group &amp;ge;8).1C: Original Western blot images and grayscale quantification values of RGC32 expression in DLBCL cell lines (OCI-LY1, OCI-LY10, etc.) versus peripheral blood mononuclear cells (PBMCs) (internal control: GAPDH).1D: RGC32 mRNA expression table quantified by RT-PCR (values: 2&amp;lt;sup&amp;gt;&amp;minus;&amp;Delta;&amp;Delta;Ct&amp;lt;/sup&amp;gt;; n=3 independent experiments).1E: Poly(A) tail length electrophoretograms and quantitative data (nucleotide counts for RGC32 mRNA in PBMCs and DLBCL cell lines).&amp;nbsp;Figure 2: RGC32 Promotes DLBCL Growth In Vitro and In VivoData Content:2A: RGC32 Western blot images of shRGC32-transduced versus control vector-treated cell lines.2B: Cell proliferation kinetics measured by CCK-8 assay (OD&amp;lt;sub&amp;gt;450nm&amp;lt;/sub&amp;gt; values at 0/24/48/72/96 hours; n=3 technical replicates).2C&amp;ndash;D: Xenograft tumor volume records (unit: mm&amp;sup3;) monitored at days 0/7/14/21/28 (n=6 mice per group).2E: H&amp;amp;E-stained and Ki-67-immunolabeled tumor tissue images (scale bar=5 &amp;mu;m).&amp;nbsp;Figure 3: Transcriptomic Signatures of shRGC32-Treated CellsData Content:3A&amp;ndash;B: Gene Ontology (GO) enrichment tables for biological processes (BP) and molecular functions (MF), including the top 10 significantly enriched terms (gene counts, padj values).3C: Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis table (top 20 pathways, enrichment factors, p-values, gene lists) derived from RNA-Seq data (shRGC32 vs. shControl; 3 biological replicates; DESeq2 pipeline with padj &amp;lt; 0.05).&amp;nbsp;Figure 4: RGC32 Knockdown Induces Cell Cycle ArrestData Content:4A: Flow cytometry-based cell cycle distribution data (percentages of cells in G0/G1, S, and G2/M phases; n=3).4B: Quantitative Western blot data for cell cycle regulators (Cyclin D1, CDK4, p27).&amp;nbsp;Figure 5: RGC32 Knockdown Enhances DNA Damage and Immune InfiltrationData Content:5A&amp;ndash;B: Original Western blot images and quantification for DNA damage pathway proteins (p-ATM, p-ATR, p-CHK1, p-H2AX) and immunomodulators (IRF1, PD-L1).5C&amp;ndash;E:Flow cytometry data (.fcs files and summary statistics) for CD3&amp;lt;sup&amp;gt;+&amp;lt;/sup&amp;gt;CD8&amp;lt;sup&amp;gt;+&amp;lt;/sup&amp;gt; T-cell infiltration in mouse tumors (% gated populations).IHC images (scale bar=5 &amp;mu;m) and scoring metrics (n=58 human DLBCL specimens) for&amp;nbsp;localization of CD8 and RGC32.</dc:description>
  <dc:subject>Response gene to complement 32 (RGC32); Diffuse large B cell lymphoma (DLBCL); Cell cycle; DNA damage repair (DDR); CD8+ T cells</dc:subject>
  <dc:creator>Xiyuan Zhang</dc:creator>
  <dc:creator>Tiange Lu</dc:creator>
  <dc:creator>Chunlei Shi</dc:creator>
  <dc:creator>Mengfei Ding</dc:creator>
  <dc:creator>Ling Wang</dc:creator>
  <dc:creator>Xinting Hu</dc:creator>
  <dc:creator>Xin Wang</dc:creator>
  <dc:rights>PUBLIC</dc:rights>
  <dc:rights>https://creativecommons.org/licenses/by-nc-nd/4.0/</dc:rights>
  <dc:type>dataset</dc:type>
  <dc:relation>http://www.doi.org/10.3389/fimmu.2025.1591615</dc:relation>
  <dc:publisher>Science Data Bank</dc:publisher>
</oai_dc:dc>

    </metadata>
</record>
</GetRecord>
</OAI-PMH>